Xenova leaps on hope for new flu treatment
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Shares in Xenova, the biotech group which is planning a £10m fundraising, jumped 21 per cent yesterday on news that its technology may have thrown up an im-pressive new treatment for flu.
Researchers at Imperial College London have found flu symptoms such as shortness of breath and inflammation of the lungs can be stopped using Xenova's OX40 molecule, which dampens the body's immune response.
Tracy Hussell, of Imperial's centre for molecular microbiology and infection, published research in the respected Journal of Experimental Medicine that suggested OX40 may prove a more lucrative molecule for Xenova than anyone had been predicting. She said: "During flu infection, the immune system has an 'all hands on deck' attitude to the viral assault. But it's this that causes most of the damage. By selectively reducing this cellular load we've shown it's possible to eliminate clinical symptoms whilst effectively tackling and clearing the infection."
David Oxlade, the chief executive of Xenova, cautioned that the experiments, conducted on mice and funded through a collaboration with the US biotech giant Genentech were only early stage work. The shares jumped 2.75p to 15.75p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments